Tufts CSDD Research Study
Current clinical partnership models often fail to integrate the multidisciplinary expertise of both partners, resulting in inefficient trial design and suboptimal patient recruitment.
In 'Optimising Collaboration Effectiveness in Alliance Partnerships', Tufts CSDD facilitated a roundtable of senior pharma industry executives investigating how to create a shared vision of the clinical development continuum through a new sustainable growth model that minimises inefficiencies in sponsor-CRO alliances and enables improved feasibility and access to patients.
Find out how to drive study performance with a framework that is designed to help you:
Today, every large sponsor has engaged in at least one alliance partnership with a CRO. As much as 50 cents on every dollar is spent on CRO support of drug development activity, according to Ken Getz from the Tufts Center for the Study of Drug Development. “Despite decades of increasing reliance on CROs, trial success rates and overall drug development cycle times have not improved,” says Mr Getz. “And the cost to develop a successful drug continues to rise.”
Explore the Untapped Value of Alliance Partnerships.